(Q39034710)

8 September 2017

title

INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells (English)

1 reference

triple-negative breast cancer

8 September 2017

1 reference

1 reference

5

Li Li

1 reference

8 September 2017

Ying Sun

1

1 reference

8 September 2017

Huan Ding

series ordinal

2

1 reference

8 September 2017

Xinguang Liu

series ordinal

3

1 reference

8 September 2017

Xiaoqing Li

series ordinal

4

1 reference

8 September 2017

publication date

14 January 2014

1 reference

8 September 2017

1 reference

8 September 2017

volume

35

1 reference

8 September 2017

issue

5

1 reference

8 September 2017

page(s)

4469-4477

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-013-1589-y

8 September 2017

exact match

0 references

cites work

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

INPP4B: the new kid on the PI3K block

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Inositol polyphosphate 4-phosphatase B as a regulator of bone mass in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Triple-negative breast cancers: an updated review on treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Basal-like breast cancer and the BRCA1 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

The Fanconi anaemia/BRCA pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Discovery and validation of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Phosphoinositide 3-kinase and INPP4B in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Basal-like breast cancer: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Triple-negative breast cancer: therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1589-Y

Understanding DNA damage response and DNA repair pathways: applications to more targeted cancer therapeutics

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24420152

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24420152

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24420152

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13277-013-1589-Y

1 reference

8 September 2017

1 reference